All In Biotech

Drug Trial Radar · NCT07529977

Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.

A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Male Participants With Androgenetic Alopecia.

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

372

Planned (sponsor's estimate)

Start

Jan 31, 2027

Primary completion

Oct 30, 2028

Study completion Oct 30, 2028

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss). The study will include male participants aged 18 to 60 years who have a clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 on the Norwood-Hamilton scale. Participants will be randomly assigned, in a 2:1 ratio, to receive either N1087 or placebo. Neither the participants nor the study team will know which treatment each participant receives. The study treatment will be taken orally once daily for a total of 24 weeks. During the first 8 weeks, the dose will be gradually increased (titration period) up to a maximum tolerated dose, not exceeding 5 mg. Participants will then continue treatment at the maximum tolerated dose for the remaining 16 weeks. The main purpose of the study is to assess whether oral minoxidil improves hair growth. The primary outcome measure is the change from baseline in the density of non-vellus hairs in a defined target area of the scalp (vertex) after 24 weeks of treatment, measured using digital phototrichogram analysis. Secondary objectives include evaluating changes in hair density at earlier time points, hair thickness, the proportion of terminal hairs, clinical improvement assessed by the investigator, quality of life related to hair loss, and participant satisfaction with treatment. The safety and tolerability of oral minoxidil will also be evaluated by monitoring adverse events, vital signs, and events of special interest throughout the study. An independent Data and Safety Monitoring Committee will oversee participant safety during the trial. This is a multicenter study conducted in Brazil, with approximately 372 participants expected to be enrolled.

Conditions

  • Androgenetic Alopecia
  • Androgenetic Alopecia (AGA)

Interventions

  • Minoxidil oral solutionDrug

    Minoxidil 5 mg/mL oral solution administered once daily. Treatment includes a dose titration period starting at 0.75 mg and gradually increasing to 1.25 mg, 2.5 mg, and up to a maximum dose of 5 mg or the maximum tolerated dose. The titration period lasts 8 weeks, followed by maintenance at the maximum tolerated dose through Week 24.

  • Placebo oral solutionDrug

    Placebo oral solution drops administered once daily. The placebo follows the same dose titration schedule and treatment duration as the experimental intervention, for a total treatment duration of 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in non-vellus hair density in the target area of the scalp (vertex)Time frame: Baseline to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eurofarma Laboratórios S.A

    Itapevi, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.